Gene-ius - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gene-ius


Pharmaceutical Technology Europe
Volume 23, Issue 8


Rich Whitworth
There have been several new stories and reports lately that paint a rather gloomy picture of the state of pharma R&D. From reports on high clinical trial failure rates (see "News") to the CEO of Eli Lilly needing to defend his position on maintaining R&D expenditure to investors, there is a message emerging, and pharma companies, or rather their investors, are beginning to question the future of R&D, and its current inability to stave off losses from patent expiries and generic competition. (I listened with interest to a news story on the radio this morning about common painkillers, such as aspirin and paracetamol, being more efficacious for dementia than antipsychotics — talk about generic competition.)

There was one beacon of light that left me feeling inspired this month, though, unfortunately, it too stems from something of an R&D failure... The Global Genes Fund aims to raise financial support for research into rare diseases, as well as increase awareness. It has a wonderful and simple message: "Every child, everywhere, regardless of disease, deserves treatments, therapies and support." It is common knowledge that the traditional pharma model does not serve orphan diseases well; pharma companies are, of course, more interested in the provision of drugs for the majority to justify R&D costs. But awareness of orphan diseases is steadily increasing, thanks to this project and other campaigns such as Rare Disease Day ( http://rarediseaseday.org/).

The fund is part of the larger US-based Global Genes Project ( http://globalgenesproject.org/), and the aim is that, in the near future, potential donors will be able to peruse research projects and make individual donations online. The idea of connecting the public directly to research activities in this way is interesting and could add incentive to tackling rare diseases. It will no doubt also leverage the vast potential of social networking and "crowdsourcing". I look forward to seeing how it could change the future landscape of R&D.

Best wishes,

Rich Whitworth, Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here